arrow_back Back to App

Ensuring Medicare Access to Innovative Diagnostic Radiopharmaceuticals

This Act ensures that Medicare beneficiaries maintain access to modern diagnostic radiopharmaceuticals used for disease detection. The change introduces a separate payment mechanism for these expensive drugs in hospital outpatient settings, instead of bundling them into the overall procedure cost. This encourages hospitals to utilize innovative, yet costly, diagnostic methods, directly improving the quality of healthcare for seniors.
Key points
Separate Payment for Costly Drugs: Medicare will pay separately for certain innovative diagnostic radiopharmaceuticals if their cost exceeds $500 (the threshold for 2024).
Improved Diagnostic Access: Hospitals will be more likely to offer the latest diagnostic methods, as their cost will no longer be absorbed by the general outpatient procedure budget.
No Impact on Patient Copayments: The change in payment method for hospitals will not affect the amount of copayments borne by Medicare patients.
Implementation Starting January 1, 2024: The new payment rules will take effect at the beginning of 2024.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1199
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
Process start date: 2023-02-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Facilitating Innovative Nuclear Diagnostics Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1199.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-02-27.

What are the main provisions?

Key points include:

  • Separate Payment for Costly Drugs: Medicare will pay separately for certain innovative diagnostic radiopharmaceuticals if their cost exceeds $500 (the threshold for 2024).
  • Improved Diagnostic Access: Hospitals will be more likely to offer the latest diagnostic methods, as their cost will no longer be absorbed by the general outpatient procedure budget.
  • No Impact on Patient Copayments: The change in payment method for hospitals will not affect the amount of copayments borne by Medicare patients.
  • Implementation Starting January 1, 2024: The new payment rules will take effect at the beginning of 2024.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Dunn, Neal P. [R-FL-2].

What is the latest detailed status?

The latest detailed status is: Forwarded by Subcommittee to Full Committee by Voice Vote.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Benefits